2.56 0.1 (4.07%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 3.47 ![]() |
1-year : | 3.93 ![]() |
Resists | First : | 2.97 ![]() |
Second : | 3.36 ![]() |
Pivot price | 2.79 ![]() |
|||
Supports | First : | 2.33 | Second : | 1.94 |
MAs | MA(5) : | 2.47 ![]() |
MA(20) : | 2.86 ![]() |
MA(100) : | 3.39 ![]() |
MA(250) : | 6.7 ![]() |
|
MACD | MACD : | -0.3 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 13.2 ![]() |
D(3) : | 7.8 ![]() |
RSI | RSI(14): 35.4 ![]() |
|||
52-week | High : | 21.87 | Low : | 2.33 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MGNX ] has closed above bottom band by 28.8%. Bollinger Bands are 27.9% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 2.59 - 2.6 | 2.6 - 2.62 |
Low: | 2.44 - 2.45 | 2.45 - 2.46 |
Close: | 2.54 - 2.56 | 2.56 - 2.58 |
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Tue, 11 Feb 2025
Further weakness as MacroGenics (NASDAQ:MGNX) drops 11% this week, taking one-year losses to 86% - Simply Wall St
Fri, 07 Feb 2025
Lost Money on MacroGenics, Inc. (MGNX)? Join Class Action Suit Seeking Recovery - Contact Levi & Korsinsky - ACCESS Newswire
Thu, 06 Feb 2025
MacroGenics, Inc. (NASDAQ:MGNX) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Sat, 14 Dec 2024
MacroGenics' SWOT analysis: oncology firm faces pipeline challenges, stock outlook mixed - Investing.com
Tue, 05 Nov 2024
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 63 (M) |
Shares Float | 52 (M) |
Held by Insiders | 2.6 (%) |
Held by Institutions | 93.6 (%) |
Shares Short | 5,280 (K) |
Shares Short P.Month | 5,400 (K) |
EPS | -1.58 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 1.9 |
Profit Margin | -69.1 % |
Operating Margin | 48.9 % |
Return on Assets (ttm) | -22.2 % |
Return on Equity (ttm) | -62.2 % |
Qtrly Rev. Growth | 964.7 % |
Gross Profit (p.s.) | -0.82 |
Sales Per Share | 2.25 |
EBITDA (p.s.) | -1.59 |
Qtrly Earnings Growth | 220.5 % |
Operating Cash Flow | -58 (M) |
Levered Free Cash Flow | -21 (M) |
PE Ratio | -1.64 |
PEG Ratio | 0 |
Price to Book value | 1.34 |
Price to Sales | 1.13 |
Price to Cash Flow | -2.78 |
Dividend | 0 |
Forward Dividend | 0 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |